The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2

MicroRNAs (miRNAs) are endogenous noncoding RNAs, about 22 nucleotides in length, that mediate post-transcriptional gene silencing by annealing to inexactly complementary sequences in the 3′-untranslated regions of target mRNAs. Our current understanding of the functions of miRNAs relies mainly on their tissue-specific or developmental stage-dependent expression and their evolutionary conservation, and therefore is primarily limited to their involvement in developmental regulation and oncogenesis. Of more than 300 miRNAs that have been identified, miR-1 and miR-133 are considered to be muscle specific. Here we show that miR-1 is overexpressed in individuals with coronary artery disease, and that when overexpressed in normal or infarcted rat hearts, it exacerbates arrhythmogenesis. Elimination of miR-1 by an antisense inhibitor in infarcted rat hearts relieved arrhythmogenesis. miR-1 overexpression slowed conduction and depolarized the cytoplasmic membrane by post-transcriptionally repressing KCNJ2 (which encodes the K+ channel subunit Kir2.1) and GJA1 (which encodes connexin 43), and this likely accounts at least in part for its arrhythmogenic potential. Thus, miR-1 may have important pathophysiological functions in the heart, and is a potential antiarrhythmic target.

[1]  M. Curtis,et al.  Quantification of arrhythmias using scoring systems: an examination of seven scores in an in vivo model of regional myocardial ischaemia. , 1988, Cardiovascular research.

[2]  L. Leinwand,et al.  Hormonal modulation of a gene injected into rat heart in vivo. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J E Saffitz,et al.  Slow ventricular conduction in mice heterozygous for a connexin43 null mutation. , 1997, The Journal of clinical investigation.

[4]  K. A. Yamada,et al.  Accelerated onset and increased incidence of ventricular arrhythmias induced by ischemia in Cx43-deficient mice. , 2000, Circulation.

[5]  R Wilders,et al.  Gap junctions in cardiovascular disease. , 2000, Circulation research.

[6]  A J Camm,et al.  Ischaemic heart disease presenting as arrhythmias. , 2001, British medical bulletin.

[7]  M. Eskandarpour,et al.  Nonsurgical Direct Delivery of Plasmid DNA Into Rat Heart: Time Course, Dose Response, and the Influence of Different Promoters on Gene Expression , 2002, Journal of cardiovascular pharmacology.

[8]  A. Lopatin,et al.  Dominant-negative suppression of I(K1) in the mouse heart leads to altered cardiac excitability. , 2003, Journal of molecular and cellular cardiology.

[9]  C. Rajamanickam,et al.  Direct injection and expression in vivo of full-length cDNA of the cardiac isoform of alpha-2 macroglobulin induces cardiac hypertrophy in the rat heart , 2003, Basic Research in Cardiology.

[10]  S. Dhein,et al.  Chronic regulation of the expression of gap junction proteins connexin40, connexin43, and connexin45 in neonatal rat cardiomyocytes. , 2004, European journal of pharmacology.

[11]  H. Cho,et al.  Selective Inhibition of Inward Rectifier K+ Channels (Kir2.1 or Kir2.2) Abolishes Protection by Ischemic Preconditioning in Rabbit Ventricular Cardiomyocytes , 2004, Circulation research.

[12]  T. Tuschl,et al.  Mechanisms of gene silencing by double-stranded RNA , 2004, Nature.

[13]  Yong Zhao,et al.  Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis , 2005, Nature.

[14]  E. Miska,et al.  MicroRNA functions in animal development and human disease , 2005, Development.

[15]  M. Byrom,et al.  Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis , 2005, Nucleic acids research.

[16]  Chaoqian Xu,et al.  Choline Produces Cytoprotective Effects Against Ischemic Myocardial Injuries: Evidence for the Role of Cardiac M3 Subtype Muscarinic Acetylcholine Receptors , 2005, Cellular Physiology and Biochemistry.

[17]  M. Curtis,et al.  Phase 2 ventricular arrhythmias in acute myocardial infarction: a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology evaluation , 2005, British journal of pharmacology.

[18]  N. Rajewsky,et al.  Silencing of microRNAs in vivo with ‘antagomirs’ , 2005, Nature.

[19]  Harvey F Lodish,et al.  Myogenic factors that regulate expression of muscle-specific microRNAs. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Jian-Fu Chen,et al.  The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation , 2006, Nature Genetics.

[21]  Zhenwei Pan,et al.  Ischemia Impairs the Association Between Connexin 43 and M3 Subtype of Acetylcholine Muscarinic Receptor (M3-mAChR) in Ventricular Myocytes , 2006, Cellular Physiology and Biochemistry.

[22]  Yvonne Tay,et al.  A Pattern-Based Method for the Identification of MicroRNA Binding Sites and Their Corresponding Heteroduplexes , 2006, Cell.

[23]  E. Olson,et al.  A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure , 2006, Proceedings of the National Academy of Sciences.

[24]  Danish Sayed,et al.  MicroRNAs Play an Essential Role in the Development of Cardiac Hypertrophy , 2007, Circulation research.